APIs in Clinical Trials: Which Data Flows to Automate First

An API in a clinical trial is a documented connection that lets one system read or write study data in another, such as a laboratory system posting results into the EDC. You automate a flow through an API when it repeats at every visit, carries values a person would otherwise re-key, and needs an audit trail.

Your study data sits in more places than your EDC: central labs, hospital records, wearables, the CTMS your operations team runs, the dashboards your sponsor reads. Someone fills each gap between two of those systems by exporting a file and re-keying values. As a data manager, you have to decide which of those gaps deserves an API and which a scheduled export handles fine.

What does an API do in a clinical trial?

An API (application programming interface) is a contract between two systems: one sends a request, the other returns or records data under agreed rules for format, authentication and access rights. In a clinical trial, an API replaces manual transfers between the EDC and the systems around it, and the receiving system logs each value it writes with its origin in the audit trail.

Three mechanisms cover most study integrations. A REST API answers requests: your dashboard asks the EDC for the number of open queries per site. A webhook pushes an event the moment it happens: a patient withdraws consent and the ePRO app stops sending reminders. A file export moves a batch on a schedule. The first two keep systems in sync, the third takes a snapshot, and the export method for analysis remains the right tool when your statistician needs a frozen dataset.

[[cta]]

Which clinical data flows are worth an API?

Four flows justify an API in most studies: laboratory results into the eCRF, source data from hospital records, readings from devices and wearables, and status data shared between the EDC and the CTMS. Each one repeats at every visit, carries values someone would re-key, and creates a transcription risk that your monitor has to catch during source data verification.

Take a phase II study with monthly blood panels at 12 sites. Without an integration, each coordinator types every hemoglobin, glucose and creatinine value from the lab report into the case report form, and the monitor checks each line against the source. With a lab API, the lab system posts the validated values with their units and reference ranges, and the monitor reviews the out-of-range results. Hospital record integrations follow the same logic through the HL7 FHIR standard, provided the hospital's IT team agrees to open the connection. Device feeds land in the ePRO module or a daily log, and the status flows are where the split between EDC and CTMS gets decided field by field.

When is a scheduled export enough?

A scheduled export beats an API when the flow runs a few times per study, when nobody acts on the data within hours, or when the receiving team needs a frozen, versioned dataset. Interim analyses, database lock transfers to biostatistics and one-off data reviews fall in that category, and an integration there costs more to maintain than it saves.

Three questions settle it. How often does the flow run: at every visit, or at a milestone? Does someone make a decision on the data within hours, as in a safety review? Who maintains the connection when a form changes? If your answers are "at milestones", "no" and "nobody", keep the export and spend the integration budget on a flow that repeats.

What breaks a clinical trial API integration?

Protocol amendments break more integrations than technology does. When a form changes, your team has to remap, test and document every field the API writes to. A Tufts CSDD study of 950 protocols found that 76% go through at least one amendment, up from 57% in 2015, with 3.3 amendments per protocol on average.

The same Tufts CSDD study measured that sites operate with different protocol versions for 215 days on average. For an integration, that means the lab or device feed has to know which form version applies to which patient, for months. Write the mapping document before the first go-live, and name the person who updates it at each amendment.

Traceability comes second. Values written by an API are electronic records like any other: if the study supports a submission to the FDA, they fall under 21 CFR Part 11, and the audit trail has to show which system wrote each value and when. The FDA's final guidance of October 2024 on electronic systems in clinical investigations addresses IT service providers and digital health technologies, and asks sponsors to scale validation to risk. The compliance requirements for EDC systems apply to the connection as much as to the screens. Subject identity comes third: a lab that works with its own accession numbers needs a mapping to your study subject IDs, tested before the first patient visit.

How is the ClinicalTrials.gov API different from a study data API?

The ClinicalTrials.gov API is a public interface to the trial registry run by the US National Library of Medicine. It returns study records such as design, status, locations and results summaries, and it gives no access to patient-level data. A study data API, like the one in an EDC, reads and writes the data your sites collect, under access control and audit trail.

Version 2 of the registry API answers at clinicaltrials.gov/api/v2/studies, returns JSON, pages results with a token and asks for no key. Its version endpoint reported version 2.0.5 in September 2026, and the ClinicalTrials.gov API documentation lists the query parameters. Feasibility and landscape teams use it to count recruiting trials in an indication or to list sites already active in a country. The registry API describes other people's trials, and it does not connect your own systems.

What should you ask a vendor before building an integration?

Five questions separate an API you can build on from a feature on a brochure: how clients authenticate, whether a test environment exists, whether webhooks exist, how API writes appear in the audit trail, and when you get the documentation. Ask them before you sign, since the answers decide your integration budget and your timeline.

• Authentication: which standard, and can you restrict each integration to the data it needs?
• Test environment: can you run the integration against test data before go-live?
• Events: can the system push a webhook on a new visit, a withdrawal or a query?
• Audit trail: does each value written by the API show its source and time stamp?
• Documentation: can your developer read it before contract signature?

These five sit alongside the rest of the EDC selection checklist.

[[cta]]

How does Datacapt handle study integrations?

Datacapt exposes a RESTful, JSON-based API on a unified clinical platform: EDC, ePRO, eConsent, randomization and the Site CTMS share one database, so an external system connects to one API to reach all of them. Clients authenticate with OAuth 2.0, access follows role-based permissions, the platform logs API activity for audit, and webhooks trigger actions on study events. A test environment lets your team validate an integration before go-live, and the Swagger documentation comes on request or at contract activation. The Datacapt API page lists the supported integrations, and the free clinical research API guide walks through a seven-step scoping method.

Start with the flow your coordinators re-key most often, which tends to be lab results, and count the minutes it costs per visit before you scope anything. An API earns its budget through repetition and traceability. The flows that run twice per study can stay exports, and the time you save goes into the mapping document that keeps the live connections working through the next amendment.

Frequently asked questions

[[faq]]